middle.news
Nyrada’s Xolatryp Clears Safety Hurdle, Phase IIa Trial Set for Early 2026
8:39am on Monday 29th of September, 2025 AEST
•
Biotechnology
Read Story
Nyrada’s Xolatryp Clears Safety Hurdle, Phase IIa Trial Set for Early 2026
8:39am on Monday 29th of September, 2025 AEST
Key Points
Phase I trial met primary safety endpoint with no serious adverse events
48 healthy participants tested across six dosing cohorts
Pharmacokinetics showed rapid, sustained therapeutic blood levels
Phase IIa trial for acute myocardial infarction patients planned for Q1 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Nyrada (ASX:NYR)
OPEN ARTICLE